-5%
Doxiva 400 is indicated for the management of:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Bronchospasm
Doxophylline is a newer bronchodilator belonging to the xanthine group. Structurally, it differs from theophylline due to the presence of a dioxolane group at position 7.
It works by selectively inhibiting phosphodiesterase-4 (PDE4), leading to relaxation of bronchial smooth muscles.
Compared to theophylline, it has lower affinity for adenosine receptors (A1 and A2), which contributes to a better safety profile and fewer side effects.
